Fabricius, Therese W. http://orcid.org/0000-0002-6344-5408
Verhulst, Clementine E. M. http://orcid.org/0000-0002-9905-7669
Kristensen, Peter L. http://orcid.org/0000-0001-5431-824X
Holst, Jens J. http://orcid.org/0000-0001-6853-3805
Tack, Cees J. http://orcid.org/0000-0003-0322-1653
McCrimmon, Rory J. http://orcid.org/0000-0002-3957-1981
Heller, Simon R. http://orcid.org/0000-0002-2425-9565
Evans, Mark L. http://orcid.org/0000-0001-8122-8987
de Galan, Bastiaan E. http://orcid.org/0000-0002-1255-7741
Pedersen-Bjergaard, Ulrik http://orcid.org/0000-0003-0588-4880
,
Funding for this research was provided by:
Innovative Medicines Initiative 2 (777460)
National Health Service in the East of England through the Clinical Academic Reserve
Copenhagen University
Article History
Received: 9 October 2023
Accepted: 13 January 2024
First Online: 20 February 2024
Decalarations
:
: TWF: Has been employed by Novo Nordisk after the completion of the study. CV: None. PLK: Has received lecture fees from AstraZeneca and Sanofi. JJH: Appears on advisory boards and has received lecture fees from Novo Nordisk. MLE: Has received personal fees from lecturing and/or advisory boards from Abbott Diabetes Care, Eli Lilly, Medtronic, Dexcom, Novo Nordisk, Astra Zeneca, Zucara and received research support from Novo Nordisk. SRH: Has served as a member of an expert panel of the U.K. CAA, and provides consultancy for Novo Nordisk, Eli Lilly, and Zealand Pharma for which his institution receives remuneration and serves on speaker panels for Novo Nordisk and Astra Zeneca for which he receives personal remuneration. RM: Has received personal fees from lecturing and/or advisory boards from Sanofi and Novo Nordisk. CT: Has received research support from AstraZeneca, served on advisory boards for Bayer, Boehringer-Ingelheim, MSD and Novo Nordisk and has received lecture fees from AstraZeneca and Novo Nordisk. BG: Has received research support from Novo Nordisk. UPB: Has served on advisory boards for Sanofi-Aventis, Novo Nordisk and Vertex and has received lecture fees from Abbott, Sanofi-Aventis and Novo Nordisk.